We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

Fintel reports that on June 3, 2025, Wolfe Research downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from ...

Fintel reports that on June 3, 2025, JMP Securities downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of ...

Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 ...

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...